Purpose
=======

According to the Cancer statistics in China of 2015[@B1], esophageal cancer (EC), mainly squamous carcinoma, is the third most commonly diagnosed cancer and the fourth most common cause of cancer death. 70% patients were more than 60 years and 20% patients were more than 75 years. As life expectancy is expected to increase over time in China [@B2], elderly esophageal cancer patients are likely to increase rapidly in the future.

Elderly patients have special characteristics including poor physiologic status and competing comorbidities, and therefore considerations should be taken into account including age, functional status, risk of treatment-related morbidities, life expectancy, and personal preference in making treatment decisions [@B3]. Due to medical comorbidities and advanced age, many elderly patients with localized esophageal squamous cell carcinoma (ESCC) are not fit for surgical resection. National comprehensive Cancer Network (NCCN) Clinical Practice Guideline has recommended 50-50.4 Gy definitive radiotherapy (RT) plus double agents chemotherapy (Fluoropyrimidine or taxane based) and the clinical tumor volume (CTV) should include coverage of elective nodal regions (Elective Nodal Irradiation, ENI) for patients unfit for surgery. However, due to underrepresentation of elderly patients in clinical trials, it is uncertain if these recommendations are fitting for patients older than 70 years of age.

Some literatures have supported that elderly patients could benefit from double agents based concurrent chemoradiotherapy (CCRT) [@B3]-[@B7]. Because substantially more toxicities could result from double chemotherapy agents CCRT (dCCRT) [@B8], [@B9], some studies use oral capecitabine or S-1 to replace infusional fluorouracil had shown excellent safety and efficacy results [@B10]-[@B12]. Single chemotherapy agents CCRT(sCCRT)with S-1 also have shown promising results [@B2].

However, many of these studies reflect small retrospective samples using somewhat heterogeneous treatment approaches, making them less useful in determining optimal CCRT/RT approaches. We have embarked on this study to address the definitive treatment approach in a large cohort of elderly Chinese ESCC patients aged ≥70 years using modern radiotherapy approaches.

Materials and methods
=====================

Patients and pretreatment evaluations
-------------------------------------

We have included 184 consecutive elderly EC patients who have received definitive CCRT/RT in Xijing Hospital between January 2010 and December 2014. All patients were ≥70 years and had ESCC, no distant metastasis at presentation and no anticancer treatment history. All cases were staged by the seventh edition of the American Joint Committee on Cancer (AJCC). Patients and treatment characteristics across different treatment modalities were summarized in Table [1](#T1){ref-type="table"}. Pretreatment evaluations included blood routine and biochemistry test, barium swallow X-ray, upper endoscopy and endoscopic ultrasonography (EUS), contrast-enhanced chest and abdomen computed tomography (CT) and ultrasonography of the neck. Magnetic resonance imaging (MRI), positron emission tomography-computed tomography (PET-CT) and bone scan were used when clinically needed. This study was approved by the ethics committee of Xijing Hospital.

Radiotherapy
------------

Radiation therapy was delivered with IMRT or VMAT. Four-dimensional CT images were obtained in all patients with distal esophageal cancer and cases with tumor motion \>1cm to allow tumor motion to be taken into consideration for treatment planning. Definition of Involved Field Irradiation (IFI) and definition of Elective Nodal Irradiation (ENI) were shown in (Supplemental figure [1](#SM0){ref-type="supplementary-material"}A-D). The prescribed doses were 50-70 Gy to the PTV for PGTVt and PGTVnd in 25 to 35 fractions and 45-54Gy for PCTVt and PCTVnd, respectively. Sequential (dose per fraction range: 1.8-2Gy) or simultaneous integrated boost (SIB) approach (dose per fraction range: 2-2.2 Gy) was applied for GTV and GTVnd dose escalation. The treatment was delivered on consecutive weekdays with a break on intervening weekend days if applicable.

Chemotherapy regimes
--------------------

47.7% patients received sCCRT including capecitabine or S1 alone, and dCCRT including cisplatin plus capecitabine or S1. The choice of chemotherapy was based on multidisciplinary team decision and patients\' preference. No patients received induction or adjuvant chemotherapy.

Follow-up evaluations
---------------------

All patients were followed up every 3 months in the first 2 years and every 6 months thereafter. Each follow-up included a physical examination, routine blood count and chemistries, barium swallow, ultrasonography of neck and abdomen, and contrast enhanced CT scans of the neck and thorax. Endoscopy with or without biopsy was recommended every 6 months or as clinically indicated. Radiotherapy-related toxicities were evaluated and scored based on the scoring criteria of the Radiation Therapy Oncology Group.

Definition of treatment failure
-------------------------------

Treatment failure was determined by pathological evidence or progression in serial posttreatment images including barium swallow, CT scans, PET-CT scans, and endoscopic evaluations. Local and regional failure was defined as the persistence or recurrence of the primary tumor or regional lymph nodes, respectively. Distant metastatic failure was defined as metastasis to any site beyond the primary tumor and regional lymph nodes. Failure location (PGTV, PCTV, or outside the radiation field) was identified by fusing current image with CT scan of the treatment plan.

Statistical analysis
--------------------

All radiation doses were converted into the equivalent dose in 2 Gy fraction (EQD2), using an α/β=10 and calculated using the prescribed dose×(10+ dose per fraction)/12. Distant failure was defined as the metastasis beyond the primary tumor and regional lymph nodes station. Overall survival (OS), loco-regional failure-free survival (LRFFS), distance metastasis free survival (DMFS), and progression-free survival (PFS), were defined as the time from the first date of therapy until the date of death, local-regional failure, distant metastasis and tumor progression respectively. And they were calculated by Kaplan-Meier method. The log-rank tests were also used for univariate analyses to select potential prognostic factors. We used *p* value less than 0.10 as cutoff to screen the factors for the subsequent multivariate analyses. Cox proportional hazard model was used for multivariate analysis. Continuous variables were dichotomized by cut-off values which were identified by receiver operating characteristic curves or based on clinical significance. Chi-square tests, Univariate and multivariate logistic regression analyses were also conducted to study any possible differences of treatment-related toxicities. All statistical analyses were performed using SPSS 18.0 (SPSS, Chicago, IL, USA) software.

Results
=======

Patients\' characteristics
--------------------------

Patient and treatment characteristics across three different treatment modalities were mostly well balanced, except that younger patients tended to get dCCRT or sCCRT, male patients and those with weight loss \< 5.0% before therapy tended to receive sCCRT compared with RT alone (Table [1](#T1){ref-type="table"}). The median age was 76 years (range, 70-91). 71.3% had stage III disease. The patients were treated by either IMRT or VMAT. The median EQD2 dosefor GTV was 61.6 Gy (range, 50-70 Gy).

Treatment efficacy
------------------

The median follow-up time was 15.5 months (interquartile range 8.0-25.4 months), The 2- and 3-year estimated OS, LRFFS, DMFS and PFS were 43.5%, 60.5%, 79.9% and 34.6%, and 35.2%, 58.5%, 77.8% and 29.4%, respectively (Figure [1](#F1){ref-type="fig"}). A total of 72 patients (39.1%) were alive at the end of the study period with a median follow-up duration of 24.0 months (interquartile range 18.8-38.5months). Median OS time was 18.6 months in this study.

Prognostic analysis
-------------------

Results of the univariate analyses for screening potential significant factors were shown in Supplement Table [1](#T1){ref-type="table"}. Of these factors, concurrent chemotherapy led to significant better OS and PFS (*p* value\<0.001). Although no significant difference was found between sCCRT and dCCRT in relation to outcomes, sCCRT was significantly associated with higher OS, LRFS, and DFS when compared with RT alone, which was shown in Figure [2](#F2){ref-type="fig"}.

Multivariate analyses showed that T stage, N stage, GTV EQD2 dose (cutoff value 56Gy) and CCRT were significant predictors for OS, N stage and CCRT were significant predictors for LRFFS, N stage was also predictive of DMFS and T stage, N stage, SIB technique and CCRT could predict PFS significantly (table [2](#T2){ref-type="table"}).

Failure patterns and salvage treatment
--------------------------------------

Failure pattern analysis and representable cases of recurrence were shown in Figure [3](#F3){ref-type="fig"}. Cumulatively, 81 patients (44%) experienced treatment failure and 47 (58%) failures were biopsy proven. The median time to any failure was 7.1 months (range 1.3-48.0 months). 53 (65.4%) and 17 (21.0%) patients had developed local and regional failure respectively. 8 (9.8%) patients developed both local and regional failures. The median time to local and regional failure was 11.0 months (range 1.9-53.9 months) and 8.8 months (range 1.5-20.7 months), respectively. 81.3% local failure occurred in PGTVt (43/53), and the others were located in PCTV (9.4%, 5/53) and out of field (9.4%, 5/53), respectively. 70.6% occurred out of radiation field (12/17), among whom 91.7% received IFI (11/12). The other regional failures were located in PGTVnd (5.9%, 1/17) and PCTV (23.5%, 4/17) respectively. sCCRT has significantly higher LRFFS compared with RT alone (69.6% vs 52%, p=0.05). Distant metastasis was noted in 30 (37.0%) patients. The median time to distant metastasis was 10.9 months (range 1.6-54.5 months). The most common metastasis sites were lung (12/30, 40.0%), liver (12/30, 40.0%), bone (8/30, 26.7%) and lower abdomen lymph nodes (2/30, 6.7%), and 4(13.3%) patients had multiple metastases.

Among 81 patients with treatment failure, 9 patients (11.1%) received salvage or palliative radiotherapy, among whom 2 received irradiation to the esophageal lesion, 4 received irradiation to the regional lymph nodes, 1 received irradiation to both esophageal lesion and regional lymph nodes and 1 received irradiation to the regional lymph nodes and stereotactic body radiation therapy to the oligometastatic lesions of the lung. At the end of the study period, 3 patients were still alive and the mean survival time for these patients were 26 months.

Toxicities
----------

The most commonly observed acute toxicity included radiation esophagitis, radiation pneumonitis, thrombocytopenia, leucopenia and gastrointestinal reactions, which were mainly mild or asymptomatic for RT alone and sCCRT group (grade 0-1). For CCRT group, the incidence of Grade ≥ 2 neutropenia (62.5% vs 37.5%) and gastrointestinal reactions (62.5% vs 37.5%)were slightly higher when compared with grade 0-1 toxicities. There were no treatment-related deaths. For the whole group, the incidence of grade 3-4 esophagitis, leucopenia, thrombocytopenia, nausea and vomiting and radiation pneumonitis were 1.6% (3/184), 6.0% (11/184, 1 for grade 4), 2.7% (5/184, 1 for grade 4), 1.1% (2/184) and 1.6% (3/184), respectively.

There was no significant difference among three treatment groups with respect to Grade 0-1 toxicities (*p*=0.580). However, patients treated with dCCRT developed significantly more grade ≥ 2 neutropenia (dCCRT vs sCCRT: 62.5% vs 24.3%, *p*=0.003; dCCRT vs RT alone: 62.5% vs 21.4%, *p*=0.002) and gastrointestinal reactions (dCCRT vs sCCRT: 62.5% vs 5.7%, *p*\<0.001; dCCRT vs RT alone: 62.5% vs 4.1%, *p*\<0.001) than patients who received sCCRT and RT alone. Although grade ≥ 2 thrombocytopenia in sCCRT was higher than that of RT alone (11.4% vs 5.1%), no significant difference was observed between these two treatment modalities (Table [3](#T3){ref-type="table"}). Furthermore, we did logistic regression analysis and found dCCRT was the only independent prediction factor for grade ≥ 2 neutropenia and gastrointestinal reactions. All the other factors, including radiation dose and treatment volumes, could not show effect on the toxicities (supplementary table [1](#SM0){ref-type="supplementary-material"} and 2).

Discussion
==========

This is a large single-institution series which focused on 184 stage 1-IIIESCC patients aged ≥70 years treated with definitive CCRT or RT alone. Our results confirmed that CCRT had significant survival benefit compared to RT alone, with similar efficacy whether chemotherapy was administered as single or double agents. Although the tradeoff of increased acute toxicities of concurrent chemotherapy was seen, sCCRT had less toxicities compared to dCCRT, and the toxicity was nearly equivalent to RT alone. These data suggest that for elderly ESCC patients, sCCRT is likely the optimal approach.

The role of CCRT in elderly EC patients remained unclear. Due to poor physiologic function, medical comorbidities, advanced age, or patient preference, many older patients with localized esophageal cancer are not candidates for surgical resection [@B3]. Definitive chemoradiation has been established by the landmark RTOG 85-01 trial[@B13], demonstrating that the addition of concurrent cisplatin-based chemotherapy to conventional fractionation RT was associated with a significantly better median survival (14 versus 9 months) and five-year survival (27 versus 0 percent) than RT alone. NCCN have recommended 50-50.4 Gy RT plus concurrent double agents chemotherapy (Fluoropyrimidine or taxane based) for EC patients unfit for surgery. For elderly EC, the results of RT alone or CCRT were sporadically reported. Xu et al reported EC patients aged \>/=70 years treated with RT alone and the 3- and 5-year OS were 13.2 and 9.2%, respectively [@B14]. As the results were not very satisfactory compared with reported CCRT results, they suggested RT alone for elderly patients with EC did not appear to be acceptable. Another study found ESCC patients aged \>70 years treated by CCRT had improved survival rates compared with RT alone, with the overall and progression-free survival in the CRT group versus the RT group were 17 months versus eight months (*P*=0.013) and 14 months versus five months (*P*=0.01), respectively[@B9]. Zhang et al also indicated that he 3-year OS rate was 36.1% for CCRT compared with 28.5% following RT alone (*p*=0.008). Multivariate analysis revealed that survival was significantly better in the CCRT group than RT alone group for patients \</= 72 years [@B5]. Our study also indicated that CCRT was a significant prognostic indicator for OS, LRFFS and PFS in elderly patients. These results suggested the value of CCRT in elderly EC patients still existed.

Although promising results were shown for CCRT in elderly patients, it has to be noted that more severe toxicities were related toCCRT compared with RT alone in elderly EC, especially for dCCRT. Cui et al found CCRT was one of the independent factors for radiation pneumonitis[@B15].Xu et al reported acute grade 3-4 esophagitis in 5.4% CCRT group and 2.7% RT group, respectively[@B9]. Zhang et al found that acute grade 3-4 hematological toxicity was identified in 36.9% and 14.5% in CCRT and RT alone patients, respectively (*p* = 0.001). CCRT patients had more grade ≥ 2 esophagitis and pneumonitis than RT alone (52.1% vs. 34.5%, p = 0.005)[@B5].We also found that patients treated with dCCRT developed significantly more grade ≥ 2 neutropenia and gastrointestinal reactions than patients who received sCCRT and RT alone. However, severe (grade 3 and 4) esophagitis was very rare (\<2%) and grade 3-4 hematological toxicity was less than 10% in our study, which might be due to advanced RT technique and optimal treatment plan utilized, furthermore, we use oral capecitabine or S-1 to replaceinfusional fluorouracil in double agents regimes, which was also recommended by NCCN guideline and has been shown to be effective in some previous studies [@B10]-[@B12].These results suggested that dCCRT should be given to patients with caution and should be used in highly selected elderly patients.

Owing to the toxicities of dCCRT, sCCRT attracted more and more attention aiming at decreasing the toxicities without compensating efficacies. A phase I trial reported oral S-1 and RT in the treatment of elderly EC patients. No grade 3 or 4 toxicity was observed at 60 and 70 mg/m2 dose levels. Endoscopic complete responsewas 66.7% andmedian OS was 29 months [@B2]. In our study, 38% patients received concurrent oral capecitabine or S-1 with RT. Our results showed that although no significant difference was found between sCCRT and dCCRTin relate to OS, both sCCRT and dCCRT were significantly associated with higher OS rate compared with RT alone. Furthermore, we observed significant less toxicities of sCCRT when compared with dCCRT and no significant difference in toxicities were observed between sCCRT and RT alone. These results strongly suggested that oral capecitabine or S-1 could be considered as an option for elderly patients who were unable to tolerate the infusional chemotherapy.

There is no consensus on the optimal RT design and delivery, especially for elderly ESCC. With the advance of RT technique from 2D to 3D, from 3DCRT to IMRT and VMAT, the survival outcome has been remarkably improved. Our results showed that CCRT/RT in elderly patients produced an excellent overall survival, with the 2- and 3-year estimated OS, LRFFS, DMFS and PFS were 43.5%, 60.5%, 79.9% and 34.6%, and 35.2%, 58.5%, 77.8% and 29.4%, respectively and the median OS time was 18.6 months in this study. These results were comparable with or slightly better than previous studies [@B4], [@B5], [@B9], [@B11], [@B16]-[@B19], which is in part due to the application VMAT and IMRT for RT.

The optimal CTVnd delineation method and RT volume remained unclear in the treatment of ESCC. Liu et al studied 169 elderly EC patients receiving IFI and ENI and the results showed that no significance difference was seen for OS and in-field recurrence and distal organ metastasis between the two groups [@B20]. Our results also showed that no significant difference was found between IFI and ENI in relation to the reported outcomes and toxicities in these studies. However, we did found among 17 patients with regional failures, 70.6% occurred out of radiation field (12/17), among whom 91.7% received IFI (11/12) and ENI method was borderline significantly associated with regional failure free survival (*p*=0.062), indicating ENI might be related to better regional control but could not translated to OS.

The optimal dose for ESCC was still controversial and 50.4Gy remained the standard [@B21]. Some studies showed that higher dose RT could generate excellent outcomes. One study indicated that the results of 66Gy irradiation alone were comparable to those in younger patients and the median survival time and overall survival rate at 3 years was 30 months and 39%, respectively^7^.Xu et al indicated that patients irradiated with a dose of \>50 Gy plus chemotherapy had a significant improved survival compared with those who receiving a dose of \</=50 Gy plus chemotherapy (18 vs. 14 months; *P*=0.049) [@B9]. We also found the GTV EQD2 dose ≥ 56 Gy was significantly associated with higher OS, DMFS and PFS (*p* value\<0.05) and GTV EQD2 dose was an independent indicator for OS (*P*=0.020, HR=0.475). However, CTV EQD2 dose (50Gy as cutoff) was not significantly related with the reported outcomes and also the regional control rate (72.6% vs 87.3%, *P*=0.384) in this study. These results suggested the potential benefit of escalating GTV dose which was also confirmed by our results showing OS, LRFFS and PFS of patients using SIB technique to boost GTV dose and higher fraction dose (\>2Gy) were both significantly higher than those using sequential boost technique and lower fraction dose (≤2 Gy) (*p* value\<0.05). The failure pattern analysis also indicated that 65.4% patients had developed local failure and 81.3% local failure occurred in PGTVt, suggesting GTV should be prescribed a relatively higher dose based on precise target delineation and rigorous quality control as well as a careful evaluation of treatment plan to balance the benefits and toxicities.

Due to the retrospective nature, this study was limited by the potential confounding factors and the single institutional nature may also limit the applicability of our findings. Therefore, well-designed, larger multi-center prospective trials may be needed. Furthermore, detailed analysis of the nutrition status and late toxicities in elderly ESCC need to be performed in future studies.

Conclusion
==========

Our results confirmed that CCRT in elderly patients aged≥70 years had significant survival benefit compared to RT alone by using modern RT techniques, especially using Single oral agent. sCCRT had substantially less toxicities compared to dCCRT, and the toxicity was equivalent to RT alone. GTV dose ≥ 56 Gy and SIB technique were good options for definitive treatment of elderly ESCC patients.
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ESCC

:   esophageal squamous cell carcinoma

RT

:   radiotherapy

CCRT

:   concurrent chemoradiation

sCCRT

:   single agent CCRT

dCCRT

:   double agents CCRT

IMRT

:   Intensity Modulated Irradiation Therapy

VMAT

:   Volumetric-Modulated Arc Therapy

SIB

:   Sequential or simultaneous integrated boost

EC

:   esophageal cancer

NCCN

:   National comprehensive Cancer Network

GTV

:   Gross tumor volume

CTV

:   clinical tumor volume

ENI

:   Elective Nodal Irradiation

AJCC

:   American Joint Committee on Cancer

EUS

:   endoscopic ultrasonography

CT

:   computed tomography

MRI

:   Magnetic resonance imaging

PET-CT

:   positron emission tomography-computed tomography

IFI

:   Involved Field Irradiation

ENI

:   Elective Nodal Irradiation

EQD2

:   equivalent dose in 2 Gy fraction

OS

:   Overall survival

LRFFS

:   loco-regional failure-free survival

DMFS

:   distance metastasis free survival

PFS

:   progression-free survival.
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###### 

Patient and treatment characteristics of elderly ESCC patients across different treatment modalities.

  Characteristics               No. of patients (%)   χ2           P                     
  ----------------------------- --------------------- ------------ ------------- ------- --------
  Age (years)                                         29.898       \<0.001a              
  \< 75                         27 (27.6%)            38 (54.3%)   15 (93.8%)            
  ≥ 75                          71 (72.4%)            32 (45.7%)   1 (6.2%)              
  Sex                                                                            6.692   0.035b
  Male                          54 (54.5%)            52 (74.3%)   11 (68.8%)            
  Female                        44 (45.5%)            18 (25.7%)   5 (31.2%)             
  Smoking (pack years)                                                           4.745   0.093
  \< 20                         74 (74.7%)            47 (67.1%)   8 (50.0%)             
  ≥ 20                          24 (25.3%)            23 (32.9%)   8 (50.0%)             
  Alcohol                                                                        3.564   0.168
  Not heavy drinking            92 (92.9%)            61 (87.1%)   13 (81.3%)            
  Heavy drinking                6 (7.1%)              9 (12.9%)    3 (18.7%)             
  Comorbidities                                                                  1.240   0.538
  No                            55 (55.6%)            44 (62.9%)   8 (50.0%)             
  Yes                           43 (44.4%)            26 (37.1%)   8 (50.0%)             
  ECOG performance status                                                        4.285   0.117
  0-1                           85 (85.9%)            63 (90.0%)   16 (100.0%)           
  2-3                           13 (14.1%)            7 (10.0%)    0 (0.0%)              
  Weight loss before therapy                                                     6.019   0.049b
  \< 5%                         55 (55.6%)            52 (74.3%)   11 (68.8%)            
  ≥ 5%                          43 (44.4%)            18 (25.7%)   5 (31.2%)             
  Weight loss during therapy                                                     4.727   0.094
  \< 5%                         73 (73.7%)            61 (87.1%)   13 (81.3%)            
  ≥ 5%                          26 (26.3%)            9 (12.9%)    3 (18.7%)             
  Primary tumor location                                                         0.581   0.748
  Upper-middle                  47 (47.5%)            32 (45.7%)   9 (56.3%)             
  Middle-lower                  51 (52.5%)            38 (54.3%)   7 (43.7%)             
  Primary tumor length                                                           0.619   0.734
  \< 6.5cm                      33 (33.3%)            25 (35.7%)   7 (43.7%)             
  ≥ 6.5cm                       65 (66.7%)            45 (64.3%)   9 (56.3%)             
  AJCC stage                                                                     3.034   0.219
  Ⅰ-Ⅱ                           17 (17.2%)            20 (28.6%)   4 (25.0%)             
  Ⅲ                             81 (82.8%)            50 (71.4%)   12 (75.0%)            
  T stage                                                                        3.462   0.177
  1-2                           12 (12.1%)            16 (22.9%)   2 (12.5%)             
  3-4                           86 (87.9%)            54 (77.1%)   14 (87.5%)            
  N stage                                                                        4.646   0.098
  1-2                           51 (52.5%)            48 (68.6%)   9 (56.3%)             
  3-4                           47 (47.5%)            22 (31.4%)   7 (43.7%)             
  Radiotherapy technique                                                         2.095   0.351
  IMRT                          60 (60.6%)            39 (55.7%)   12 (75.0%)            
  VMAT                          38 (39.4%)            31 (44.3%)   4 (25.0%)             
  CTVnd delineation                                                              2.150   0.341
  IFI                           72 (72.7%)            58 (82.9%)   12 (75.0%)            
  ENI                           26 (27.3%)            12 (17.1%)   4 (25.0%)             
  Dose boost schemes                                                             2.611   0.271
  No SIB                        34 (34.3%)            28 (40.0%)   3 (18.7%)             
  SIB                           64 (65.7%)            42 (60.0%)   13 (81.3%)            
  Fraction dose (Gy)                                                             0.917   0.632
  ≤ 2                           57 (57.6%)            36 (51.4%)   8 (50.0%)             
  \> 2                          41 (42.4%)            34 (48.6%)   8 (50.0%)             
  Radiation dose for GTV (Gy)                                                    1.208   0.547
  \< 56                         15 (15.2%)            11 (15.7%)   1 (6.2%)              
  ≥ 56                          83 (84.8%)            59 (84.3%)   15 (93.8%)            
  Radiation dose for CTV (Gy)                                                    2.315   0.314
  \< 50                         17 (17.2%)            10 (14.3%)   5 (31.2%)             
  ≥ 50                          81 (82.8%)            60 (85.7%)   11 (68.8%)            

Abbreviations: ECOG, eastern cooperative oncology group; IMRT, intensity-modulated radiotherapy; VMAT, volumetric-modulated arc therapy; GTV, gross tumor volume; CTV: clinical target volume; IFI, involved field irradiation; ENI, elective nodal irradiation; SIB, simultaneous integrated boost.

*p* values less than 0.05 are highlighted in bold.

^a^ There were significant difference among the three groups.

^b^ There were significant difference between RT alone and Single agent CRT group.

###### 

Multivariateanalysis of prognostic factorson treatment resultsfor elderly EC.

  Endpoint       Prognostic factors                              Multivariateanalysis   
  -------------- ----------------------------------------------- ---------------------- ---------------------
  **3y OS**      T stage (1-2*vs*3-4)                            0.039                  2.205(1.041-4.672)
                 N stage (0-1*vs*2-3)                            \<0.001                3.093 (1.861-5.140)
                 GTV dose (\< 56Gy *vs*≥ 56Gy)                   0.020                  0.475 (0.254-0.889)
                 Concurrent chemotherapy (No *vs* Yes)           0.001                  0.413 (0.249-0.686)
  **3y LRFFS**   N stage(0-1*vs*2-3)                             \<0.001                3.815 (1.959-7.432)
                 Concurrent chemotherapy (No *vs* Yes)           0.033                  0.489 (0.254-0.943)
  **3y DMFS**    N stage(0-1*vs*2-3)                             0.035                  2.252 (1.060-4.782)
  **3y PFS**     T stage (1-2*vs*3-4)                            0.028                  1.971 (1.076-3.613)
                 N stage (0-1*vs*2-3)                            \<0.001                2.642 (1.829-3.816)
                 Dose boost schemes (sequential boost*vs* SIB)   0.010                  0.608 (0.416-0.889)
                 Concurrent chemotherapy (No *vs* Yes)           0.001                  0.537 (0.370-0.780)

Abbreviations: OS, overall survival; LRFFS, local-regional failure-free survival; DMFS,distance metastasis free survival; PFS, progression-free survival; HR, hazard ratio; 95% CI, 95% confidence interval.

###### 

Treatment related toxicities.

  Toxicities                  RT alone              Single agent CRT              Double agents\' CRT   χ2   P                                            
  --------------------------- ---------- ---------- ------------------ ---------- --------------------- ---- ---------- ---------- -------- ---------- -- --
  Neutropenia                 77(78.6)   21(21.4)                      53(75.7)   17(24.3)                   6(37.5)    10(62.5)   10.602   0.005a        
  Thrombocytopenia            93(94.9)   5(5.1)                        62(88.6)   8(11.4)                    13(81.2)   3(18.8)    4.030    0.133         
  Radiation esophagitis       79(80.6)   19(19.4)                      59(83.3)   11(15.7)                   11(68.8)   5(31.2)    1.893    0.388         
  Radiation pneumonia         91(92.9)   7(7.1)                        67(95.7)   3(4.3)                     15(93.8)   1(6.2)     0.619    0.734         
  Gastrointestinal reaction   94(95.9)   4(4.1)                        66(94.3)   4(5.7)                     6(37.5)    10(62.5)   32.605   \<0.001b      
                                                                                                                                                          

p values less than 0.05 were highlighted in bold.

a: Double agentsvs Single agent CRT, P = 0.003; Double agents\' CRT VS RT alone, P = 0.002

b: Double agents VS Single agent CRT, P \< 0.001; Double agents\' CRT VS RT alone, P\< 0.001
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